吉非替尼联合西妥昔单抗对人肠癌Lovo细胞作用的研究

目的 通过研究吉非替尼与西妥昔单抗的不同给药方案对人肠癌Lovo细胞的杀伤作用,探讨两药单药或联合使用对肠癌的作用结果。方法 通过PCR扩增后产物直接测序的方法筛选肠癌细胞,以药物联合效应测定方法,评价吉非替尼和西妥昔单抗不同时间、浓度、给药顺序对K-ras基因没有发生突变的肠癌Lovo细胞的抑制作用,流式细胞仪测定最佳方案对Lovo细胞周期分布及凋亡率的影响。结果 证实药物诱导细胞凋亡存在,吉非替尼联合西妥昔单抗对Lovo细胞的抑制作用优于单药的分别作用,而不同浓度、时间、给药顺序没有显著差异(P＞0.05)。结论 吉非替尼与西妥昔单抗联合应用对人肠癌Lovo细胞的增殖存在抑制作用。

Synergistic effect of Gefitinib and Cetuximab on human colorectal cancer cell line Lovo

Objective To study killing effects of different dosage regimens of Gefitinib in combination with Cetuximab on Lovo cells （human colorectal cancer cell line）for exploring effects of Gefitinib and Cetuximab alone or combined on colorectal cancer. Methods Colorectal cancer cells were selected by direct sequencing of products after PCR amplification. Inhibiting effects of Gefitinib and Cetuximab of different times, concentrations and administration orders on Lovo cells with no K - ras mutation were evaluated by determination of combined effects of both drugs. Influence of optimal dosage regimen on ce],l cycle distribution and apoptosis rate of Lovo ceils was determined by flow cytometry. Results Iit was confirmed that both Gefitinib and Cetuximab could in- duce apoptosis, and inhibitive effects of Gefitinib in combination with Cetuximab on Lovo cells were significantly stronger than that of Gefitinib or Cetuximab alone;However,different times, concentrations and administration or- ders of both agents did no produce significant difference （ P 〉 0.05 ）. Conclusion Gefitinib in combination with Cetuximab could produce inhibitive effects on proliferation of Lovo cells.